# EG 427

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eg-427

- Industry: Biotechnology
- Headquarters: Paris, France
- Website: www.cyllene-tx.com
- Total disclosed funding: $52M
- Latest round: Series C (Sep 8, 2026)
- Investors on record: 6

## About

Based in Paris, France, and founded in 2019, Cyllene Therapeutics, formerly known as EG 427, is a biotechnology company that engages in the research and development of novel approach in gene therapy called pinpoint gene therapy. In 2019, the company developed its own HSV-1 vector technology and demonstrated preclinical proof of concept in the most frequent kind of neurogenic bladder (urinary bladder dysfunction due to supra-sacral spinal cord injury). In July 2026, Cyllene Therapeutics raised EUR 33 million series C funding co-led by GordonMD and M Ventures, with participation from Andera Partners SAS, Bpifrance Investissement, and Lamond Capital Partners.

EG 427 develops HSV-1-based vectors by using the natural qualities of Herpes Simplex Virus 1 (HSV-1) and, in particular, its capacity to define lifetime latency in peripheral neurons to ensure extremely specific and durable expression of transgenes in patients with severe, chronic, and localized illnesses, beginning with peripheral system problems, allowing physicians to cure bladder cancer. The firm plans to use the July 2023 funding to progress more pipeline items and advance the clinical development of EG110A.

The company will use the July 2026 funding to support the continued clinical development of EG110A for severe chronic neuro-urology indications and expand its HERMES non-replicating HSV-1 platform.

## Funding rounds

- Series C, Sep 8, 2026, $23M — Andera Partners, M Ventures, Lamond Capital Partners, Bpifrance Investissement, GordonMD Global Investments
- Series B, Feb 20, 2025, $28M — Andera Partners, Bpifrance Investissement, SCI Ventures

## Investors

- Andera Partners (https://capitalatlas.ai/funds/andera-partners) — Series B, Series C
- Bpifrance Investissement (https://capitalatlas.ai/funds/bpifrance-investissement) — Series B, Series C
- SCI Ventures — Series B
- M Ventures (https://capitalatlas.ai/funds/m-ventures) — Series C
- Lamond Capital Partners — Series C
- GordonMD Global Investments (https://capitalatlas.ai/funds/gordonmd-global-investments) — Series C